Axsome Therapeutics, Inc.

As of August 9, 2022, Axsome Therapeutics is considered a risky investment due to its high price-to-book value of 103.56 and negative earnings metrics, despite a strong year-to-date return of 40.21%.

As of August 9, 2022, Axsome Therapeutics, Inc. is considered overvalued and risky, with a price-to-book ratio of 103.56, an EV to EBITDA of -23.34, and a return on equity of -464.66%, contrasting sharply with healthier peers like Halozyme Therapeutics, Inc. which has a P/E ratio of 13.48.

As of March 28, 2025, Axsome Therapeutics, Inc. shows a mildly bullish trend overall, supported by monthly indicators, despite mixed signals from weekly MACD and KST suggesting some weakness in buying pressure.

As of March 2022, the management team of Axsome Therapeutics, Inc. includes Dr. Herriot Tabuteau as Chairman, President, and CEO, with Dr. Roger Jeffs as Lead Independent Director, and Dr. Mark Coleman and Mr. Mark Saad as Independent Directors.

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. As of March 2025, it reported net sales of $121 million and a net loss of $59 million, with a market cap of approximately $5 billion.

As of Jun 18, Axsome Therapeutics, Inc. has a market capitalization of $5.00 billion, with net sales of $432.16 million and a net profit of -$278.26 million over the last four quarters. The company reported shareholder's funds of $57.02 million and total assets of $568.50 million as of Dec 24.